Children with solid tumors often present a diagnostic challenge to the oncology team. Identifying the tissue of origin and final pathology assignment is a multi step process. Molecular pathogenesis has improved and refined the diagnostic process of many solid tumors. Tumor-specific genetic aberrations provide diagnostic precision and play a role in prognosticating staging as well as potential response to therapy. This presentation focused on the diagnostic process from initial presentation through identification and final treatment assignment of patients with Rhabdomyosarcoma.
Hanna Tseitlin, RN(EC), MN, PNP
Pediatric Oncology Nurse Practitioner
McMaster Children’s Hospital, Hamilton